B.1.1.529 variant named Omicron, designated as a Variant of concern (VOC) by WHO

WHO’s Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) was convened on 26th November 2021 to assess the variant B.1.1.529. Based on the available evidences, the group of experts has advised WHO that this variant should be designated as a Variant of concern (VOC), and named Omicron. 

The B.1.1.529 variant was first reported to WHO from South Africa on 24th November 2021. The first known confirmed B.1.1.529 infection was from a specimen collected on 9th November 2021. Since then, the number of COVID-19 cases has steeply increased in almost all provinces in South Africa. This variant is characterised by a large number of mutations. Apparently, there is an increased risk of reinfection with this variant, as compared to others.  

Hence, based on the available evidences, the expert group has advised WHO that this variant should be designated as a VOC, and named Omicron. 

A variant of concern (VOC) is a variant of interest (VOI) that has shown an increase in transmissibility and/or virulence and/or decrease in effectiveness of public health measures at a degree of global public health significance: 

Individuals are reminded to take appropriate COVID-19 measures to reduce their risk of disease, including proven public health and social measures such as wearing well-fitting masks, hand hygiene, physical distancing, improving ventilation of indoor spaces, avoiding crowded spaces, and getting vaccinated. 

 *** 

Source:  

WHO 2021. News – Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Published 26 November 2021. Available online at https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern  

Latest

UK’s First Birth Following Living-donor Uterine Transplantation

The woman who had undergone the first living-donor uterus...

Qfitlia (Fitusiran): A Novel siRNA-based Treatment for Haemophilia  

Qfitlia (Fitusiran), a novel siRNA-based treatment for haemophilia has...

JWST’s Deep Field Observations Contravene Cosmological Principle

James Webb Space Telescope’s deep field observations under JWST...

Long-chain Hydrocarbons Detected on Mars  

An analysis of existing rock sample inside Sample Analysis at...

Newsletter

Don't miss

CoViNet: A New Network of Global Laboratories for Coronaviruses 

A new global network of laboratories for coronaviruses, CoViNet,...

COVID-19: Severe lung infection affects heart through “cardiac macrophage shift” 

It is known that COVID-19 increases the risk of...

JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25...

COVID-19: JN.1 sub-variant has higher transmissibility and immune escape ability 

Spike mutation (S: L455S) is hallmark mutation of JN.1...

COVID-19 Not Over Yet: What We Know of the Latest Surge in China 

It is perplexing why China chose to lift zero-COVID...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

CoViNet: A New Network of Global Laboratories for Coronaviruses 

A new global network of laboratories for coronaviruses, CoViNet, has been launched by WHO. The aim behind this initiative is to bring together surveillance...

Ischgl Study: Development of Herd Immunity and Vaccine Strategy against COVID-19

Routine sero-surveillance of the population to estimate presence of antibodies to COVID-19 is required to understand the development of herd immunity in a population....

2-Deoxy-D-Glucose(2-DG): A Potentially Suitable anti-COVID-19 drug

2-Deoxy-D-Glucose(2-DG), a glucose analog that inhibits glycolysis, has recently received Emergency Use Authorization (EUA) in India for the treatment of moderate to severe COVID-19 patients....